Literature DB >> 6429097

Elective ilioinguinal lymph node irradiation.

R H Henderson, J T Parsons, L Morgan, R R Million.   

Abstract

Most radiologists accept that modest doses of irradiation (4500-5000 rad/4 1/2-5 weeks) can control subclinical regional lymph node metastases from squamous cell carcinomas of the head and neck and adenocarcinomas of the breast. There have been few reports concerning elective irradiation of the ilioinguinal region. Between October 1964 and March 1980, 91 patients whose primary cancers placed the ilioinguinal lymph nodes at risk received elective irradiation at the University of Florida. Included are patients with cancers of the vulva, penis, urethra, anus and lower anal canal, and cervix or vaginal cancers that involved the distal one-third of the vagina. In 81 patients, both inguinal areas were clinically negative; in 10 patients, one inguinal area was positive and the other negative by clinical examination. Tumor doses most commonly used were 4500-5000 rad/5 weeks (180 rad to 200 rad per fraction). With a minimum two-year follow-up, there were only two regional failures in patients whose primaries were controlled; both failures occurred outside of the radiation fields. The single significant complication was a bilateral femoral neck fracture. The inguinal areas of four patients developed mild to moderate fibrosis. One patient with moderate fibrosis had bilateral mild leg edema that was questionably related to irradiation. No other instances of leg or genital edema were noted. Complications were dose-related. The advantages and disadvantages of elective ilioinguinal node irradiation versus elective inguinal lymph node dissection or no elective treatment are discussed.

Entities:  

Mesh:

Year:  1984        PMID: 6429097     DOI: 10.1016/0360-3016(84)90381-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  The potential impact on costs and staffing of introducing clinical networks and British Association of Perinatal Medicine standards to the delivery of neonatal care.

Authors:  E S Draper; B N Manktelow; C McCabe; D J Field
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-05       Impact factor: 5.747

Review 2.  Primary groin irradiation versus primary groin surgery for early vulvar cancer.

Authors:  Jacobus van der Velden; Guus Fons; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

3.  Sentinel lymph node in patients with rectal cancer invading the anal canal.

Authors:  D C Damin; G C Tolfo; M A Rosito; B L Spiro; L M Kliemann
Journal:  Tech Coloproctol       Date:  2010-04-28       Impact factor: 3.781

4.  Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer?

Authors:  W M Mendenhall; K I Bland; E M Copeland; G E Summers; W W Pfaff; W W Souba; R R Million
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

5.  Necessity of external iliac lymph nodes and inguinal nodes radiation in rectal cancer with anal canal involvement.

Authors:  Rong Zheng; YaZhen Zhang; RunFan Chen; Bingjie Guan; YuPing Lin; BiSi Wang; XiaoBo Li; Pan Chi; XiaoPing Chen; BenHua Xu
Journal:  BMC Cancer       Date:  2022-06-14       Impact factor: 4.638

6.  Preoperative radiation therapy for clinically resectable adenocarcinoma of the rectum.

Authors:  W M Mendenhall; R R Million; K I Bland; W W Pfaff; E M Copeland
Journal:  Ann Surg       Date:  1985-08       Impact factor: 12.969

7.  Initially unresectable rectal adenocarcinoma treated with preoperative irradiation and surgery.

Authors:  W M Mendenhall; R R Million; K I Bland; W W Pfaff; E M Copeland
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

8.  Anal adenocarcinoma requires prophylactic inguinal nodal treatment: Results from a single Chinese institution.

Authors:  Zhen Su; Zhan-Wen Guo; Yan-Ping Mao; Jie Tang; Xiao-Wen Lan; Fang-Yun Xie; Qun Li
Journal:  J Cancer       Date:  2017-04-09       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.